ELE-LSD as a potential treatment for Alzheimer's Disease

Eleusis is planning to conduct a Phase I study investigating using ELE-LSD as a treatment for Alzheimer’s Disease. ELE-LSD is a low-dose LSD product.

The results of a previous Phase-I study can be found here.

At present, no information is available on the status of this trial.

Compound LSD

Country United States of America

Visit trial

Status Planned

Results Published

Design Open

Type Interventional

Generation First

Sex All

Therapy No

Trial Details

NCT Number

Sponsors & Collaborators

Eleusis
Eleusis is a clinical-stage life sciences company that studies and develops psychedelic drugs for therapeutic use. Since 2013 the company has been researching psychedelics and is now developing ELE-Psilo (psilocybin) for depression that is in Phase I.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.